Portal:CPTAC/Hallmark/Resisting
From WikiPathways
(Difference between revisions)
(updating list) |
Current revision (00:05, 4 December 2018) (view source) (Added descriptive summary) |
||
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | *[[Pathway:WP254]] | + | Tumor cells use a variety of strategies to limit or circumvent apoptosis. Most common is the loss of TP53 tumor suppressor function, which eliminates this critical damage sensor from the apoptosis-inducing circuitry. Alternatively, tumors may achieve similar ends by increasing expression of antiapoptotic regulators (Bcl-2, Bcl-xL) or of survival signals (Igf1/2), by downregulating proapoptotic factors (Bax, Bim, Puma), or by short-circuiting the extrinsic ligand-induced death pathway. (Adapted from [https://www.ncbi.nlm.nih.gov/pubmed/21376230 Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011]) |
| - | *[[Pathway:WP3982]] | + | *[[Pathway:WP254]] Apoptosis |
| - | *[[Pathway:WP1742]] | + | *[[Pathway:WP3982]] miRNA regulation of p53 pathway in prostate cancer |
| + | *[[Pathway:WP1742]] TP53 Network | ||
| + | *[[Pathway:WP3844]] PI3K-AKT-mTOR signaling pathway and therapeutic opportunities | ||
| + | *[[Pathway:WP1471]] Target Of Rapamycin (TOR) Signaling | ||
Current revision
Tumor cells use a variety of strategies to limit or circumvent apoptosis. Most common is the loss of TP53 tumor suppressor function, which eliminates this critical damage sensor from the apoptosis-inducing circuitry. Alternatively, tumors may achieve similar ends by increasing expression of antiapoptotic regulators (Bcl-2, Bcl-xL) or of survival signals (Igf1/2), by downregulating proapoptotic factors (Bax, Bim, Puma), or by short-circuiting the extrinsic ligand-induced death pathway. (Adapted from Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011)
- Pathway:WP254 Apoptosis
- Pathway:WP3982 miRNA regulation of p53 pathway in prostate cancer
- Pathway:WP1742 TP53 Network
- Pathway:WP3844 PI3K-AKT-mTOR signaling pathway and therapeutic opportunities
- Pathway:WP1471 Target Of Rapamycin (TOR) Signaling
